공시 • Dec 23
Entheon Biomedical Corp. (CNSX:ENBI) signed a letter of intent to acquire Entheon Biomedical Corp. for CAD 5.33 million in a reverse merger transaction. Nutravisor Inc. signed a letter of intent to acquire Entheon Biomedical Corp. (CNSX:ENBI) for CAD 5.33 million in a reverse merger transaction on December 18, 2025. Under the terms of the LOI, Entheon has agreed to issue an aggregate of 53,333,333 shares of Entheon to existing shareholders of Nutravisor at a per share price equal to CAD 0.75 for aggregate consideration equal to approximately CAD 40 million on a post-consolidation basis. Entheon shall be required to complete an approximately 6.93:1 share consolidation such that the value allocated to Entheon shareholders shall be CAD 1.5 million. A finder's fee in the amount of CAD 0.5 million is being paid in connection with the Proposed Transaction. Upon completion of the Proposed Transaction, the combined entity will continue the business of Nutravisor. Following the transaction, Nutravisor's existing management team will assume leadership of the Resulting Issuer. All but one of the directors of Entheon shall resign and the board of directors will be comprised of directors nominated by Nutravisor. Entheon is expected to change its name concurrent with closing, subject to regulatory approval. The Definitive Agreement is expected to be executed in January, 2026. The LOI contains customary deal protection provisions, including a mutual break fee in the amount of CAD 0.04 million payable if the Proposed Transaction is terminated by either party under certain specific circumstances. A finder's fee in the amount of CAD 0.5 million is being paid in connection with the Proposed Transaction.
The transaction is expected to close on or before March 30, 2026, subject to satisfactory tax, corporate and securities law advice for both Entheon and Nutravisor and will be set forth in a definitive agreement to be entered into among the parties, Execution of the Definitive Agreement, Completion of satisfactory due diligence, Receipt of all required regulatory, corporate, and shareholder approvals, Acceptance of the Proposed Transaction by the Canadian Securities Exchange, Receipt of approval for the listing of the common shares of the Resulting Issuer by the CSE, Completion of the Concurrent Offering, Delivery of financial statements of both Entheon and Nutravisor; and No material adverse changes in either party. 공시 • Oct 14
Entheon Biomedical Corp., Annual General Meeting, Dec 15, 2025 Entheon Biomedical Corp., Annual General Meeting, Dec 15, 2025. 공시 • Apr 08
Entheon Biomedical Corp. Announces Board Changes Entheon Biomedical Corp. appointed Harrison Newlands to the Company's Board of Directors, effective April 3, 2025. Harrison Newlands has a diverse understanding of start-ups and capital markets, having invested, advised, and helped co-found dozens of mid-cap companies spanning close to a decade of experience in the industry. He started his career working on Bay Street as a Research Associate at MacNicol and Associates, thereafter he jumped into the fast growing cannabis industry, and was one of the co-founders of Fire & Flower, one of Canada's first retail focused cannabis companies, where he led its early growth and served as Director of Business Development. Shortly thereafter, he helped take the first EV company public in Canada, Taiga Motors, where he served as a strategic advisor. Mr. Newlands also co-founded Hoshi International, a producer of medicinal cannabis with a state of the art facility in Portugal, focusing on the emerging European market. Harrison also co-founded Hypercharge Networks, Canada's first publicly traded EV charging company. Harrison was formerly a partner at Rockbank Capital, a Vancouver based merchant bank, and has been a managing partner at North King Capital over the past 4 years, where he continues to advise both public and private companies, as well as invest. Andrew Hegle has resigned from the Company's Board of Directors. 공시 • Jan 07
Entheon Biomedical Corp. announced that it has received CAD 0.5 million in funding On January 6, 2025. Entheon Biomedical Corp. closed the transaction. 공시 • Dec 03
Entheon Biomedical Corp. announced that it expects to receive CAD 0.3 million in funding Entheon Biomedical Corp. announced a non-brokered private placement of 30,000,000 units at a price of CAD 0.1 per unit for gross proceeds of CAD 3,000,000 on December 2, 2024. Each unit consists of one common share of the company and one transferable share purchase warrant, with each warrant exercisable for one additional share at an exercise price of CAD 0.15 per share for a period of 24 months from the date of issuance. All securities to be issued will be subject to a four-month and a day hold period. The Company may pay finder's fees in accordance with the policies of the Canadian Securities Exchange. 공시 • Oct 15
Entheon Biomedical Corp., Annual General Meeting, Dec 16, 2024 Entheon Biomedical Corp., Annual General Meeting, Dec 16, 2024. Location: vancouver Canada 공시 • Apr 20
Entheon Biomedical Corp. announced that it has received CAD 0.1475 million in funding On April 18, 2024, Entheon Biomedical Corp. closed the transaction. All securities issued under the placement are subject to a hold period of four months and one day expiring on Aug. 19, 2024. 공시 • Apr 12
Entheon Biomedical Corp. announced that it expects to receive CAD 0.1475 million in funding Entheon Biomedical Corp. announced a private placement of up to 2,950,000 units at a price of CAD 0.05 per unit for gross proceeds of up to CAD 147,500 on April 11, 2024. Each unit will consist of one common share and one transferable share purchase warrant. Each warrant will be exercisable to acquire one additional share at an exercise price of CAD 0.10 per share for a period of 60 months from the date of issuance. All securities issued under the placement will be subject to a four-month and one-day hold period. The company may pay finder’s fees in accordance with the policies of the Canadian Securities Exchange. 공시 • Oct 31
Entheon Biomedical Corp., Annual General Meeting, Dec 29, 2023 Entheon Biomedical Corp., Annual General Meeting, Dec 29, 2023. Location: Vancouver Vancouver Canada 공시 • Aug 01
Entheon Biomedical Corp. Announces Termination of Andrew Hegle as Chief Science Officer Entheon Biomedical Corp. announced that the company has terminated Andrew Hegle's position as Chief Science Officer, effective July 31, 2023. Mr. Hegle will continue on the Company's Board of Directors. 공시 • Feb 18
Entheon Biomedical Corp., Annual General Meeting, Apr 19, 2023 Entheon Biomedical Corp., Annual General Meeting, Apr 19, 2023. 공시 • Jan 07
Entheon Biomedical Corp. Announces CFO Changes Entheon Biomedical Corp. announced the appointment of Soo-Whan Kim as Interim Chief Financial Officer of the Company, effective immediately. Mr. Kim brings over 12 years of experience working in senior finance positions of publicly traded companies. Mr. Kim serves as the Chief Financial Officer of Western Metallica Resources Corp. and as Corporate Controller of Consolidated Uranium and Labrador Uranium. He was previously Director of Treasury & Planning at Americas Gold & Silver and Corporate Controller at Andean Precious Metals and Polar Star Mining. Mr. Kim began his career at BDO Canada where he worked with numerous companies across various sectors. Mr. Kim is a Chartered Professional Accountant (CPA, CA) and holds a Bachelor of Commerce from the Ted Rogers School of Management at Toronto Metropolitan University. Mr. Kim replaces Brandon Schwabe as Chief Financial Officer.